p53 contributes to T cell homeostasis through the induction of pro-apoptotic SAP

Cell Cycle

Volumn 11, Issue 24, 2012, Pages 4563-4569

  Madapura, Harsha S ^a   Salamon, Daniel ^a   Wiman, Klas G ^a   Lain, Sonia ^a   Klein, George ^a   Klein, Eva ^a   Nagy, Noémi ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Apoptosis; p53; SAP; T cell homeostasis; X linked lymphoproliferative disease

Indexed keywords

NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NUTLIN 3; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; PUMA PROTEIN; SIGNALING LYMPHOCYTE ACTIVATION MOLECULE ASSOCIATED PROTEIN;

APOPTOSIS; ARTICLE; CELL DEATH; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; HOMEOSTASIS; HUMAN; HUMAN CELL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; UPREGULATION;

EID: 84871475053     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.22810     Document Type: Article

References (38)

1. Vousden KH, Prives C. Blinded by the Light: The Growing Complexity of p53. Cell 2009; 137:413-31; PMID:19410540; http://dx.doi.org/10.1016/j.cell. 2009.04.037.
2. Lin J, Chen J, Elenbaas B, Levine AJ. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev 1994; 8:1235-46; PMID:7926727; http://dx.doi.org/10.1101/gad.8.10.1235.
3. Purtilo DT. X-linked lymphoproliferative syndrome. An immunodeficiency disorder with acquired agammaglobulinemia, fatal infectious mononucleosis, or malignant lymphoma. Arch Pathol Lab Med 1981; 105:119-21; PMID:6894075.
4. Veillette A. Immune regulation by SLAM family receptors and SAP-related adaptors. Nat Rev Immunol 2006; 6:56-66; PMID:16493427; http://dx.doi.org/10. 1038/nri1761.
5. Nagy N, Matskova L, Kis LL, Hellman U, Klein G, Klein E. The proapoptotic function of SAP provides a clue to the clinical picture of X-linked lymphoproliferative disease. Proc Natl Acad Sci USA 2009; 106:11966-71; PMID:19570996; http://dx.doi.org/10.1073/pnas.0905691106.
6. Sullivan JL. The abnormal gene in X-linked lymphoproliferative syndrome. Curr Opin Immunol 1999; 11:431-4; PMID:10448142; http://dx.doi.org/10.1016/ S0952-7915(99)80072-7.
7. Nagy N, Takahara M, Nishikawa J, Bourdon JC, Kis LL, Klein G, et al. Wild-type p53 activates SAP expression in lymphoid cells. Oncogene 2004; 23:8563-70; PMID:15378026; http://dx.doi.org/10.1038/sj.onc.1207908.
8. Bode AM, Dong Z. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 2004; 4:793-805; PMID:15510160; http://dx.doi.org/10.1038/ nrc1455.
9. Banin S, Moyal L, Shieh S, Taya Y, Anderson CW, Chessa L, et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 1998; 281:1674-7; PMID:9733514; http://dx.doi.org/10.1126/science.281.5383.1674.
10. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303:844-8; PMID:14704432; http://dx.doi.org/10.1126/science. 1092472.
11. Nagy N, Cerboni C, Mattsson K, Maeda A, Gogolák P, Sümegi J, et al. SH2D1A and SLAM protein expression in human lymphocytes and derived cell lines. Int J Cancer 2000; 88:439-47; PMID:11054674; http://dx.doi.org/10.1002/ 1097-0215(20001101)88:3<439::AID-IJC17>3.0.CO;2-#.
12. Nagy N, Maeda A, Bandobashi K, Kis LL, Nishikawa J, Trivedi P, et al. SH2D1A expression in Burkitt lymphoma cells is restricted to EBV positive group I lines and is downregulated in parallel with immunoblastic transformation. Int J Cancer 2002; 100:433-40; PMID:12115526; http://dx.doi.org/10.1002/ijc.10498.
13. Parolini S, Bottino C, Falco M, Augugliaro R, Giliani S, Franceschini R, et al. X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells. J Exp Med 2000; 192:337-46; PMID:10934222; http://dx.doi.org/10.1084/jem.192.3.337.
14. Ma CS, Deenick EK. The role of SAP and SLAM family molecules in the humoral immune response. Ann NY Acad Sci 2011; 1217:32-44; PMID:21091715; http://dx.doi.org/10.1111/j.1749-6632.2010.05824.x.
15. Snow AL, Marsh RA, Krummey SM, Roehrs P, Young LR, Zhang K, et al. Restimulation-induced apoptosis of T cells is impaired in patients with X-linked lymphoproliferative disease caused by SAP deficiency. J Clin Invest 2009; 119:2976-89; PMID:19759517.
16. Coffey AJ, Brooksbank RA, Brandau O, Oohashi T, Howell GR, Bye JM, et al. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet 1998; 20:129-35; PMID:9771704; http://dx.doi.org/10.1038/2424.
17. Nichols KE, Harkin DP, Levitz S, Krainer M, Kolquist KA, Genovese C, et al. Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proc Natl Acad Sci USA 1998; 95:13765-70; PMID:9811875; http://dx.doi.org/10.1073/pnas.95.23.13765.
18. Sayos J, Wu C, Morra M, Wang N, Zhang X, Allen D, et al. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature 1998; 395:462-9; PMID:9774102; http://dx.doi.org/ 10.1038/26683.
19. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80:293-9; PMID:7834749; http://dx.doi.org/10.1016/0092-8674(95)90412-3.
20. Owen-Schaub LB, Zhang W, Cusack JC, Angelo LS, Santee SM, Fujiwara T, et al. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol 1995; 15:3032-40; PMID:7539102.
21. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. A model for p53-induced apoptosis. Nature 1997; 389:300-5; PMID:9305847; http://dx.doi.org/10.1038/38525.
22. Nagy N, Matskova L, Hellman U, Klein G, Klein E. The apoptosis modulating role of SAP (SLAM associated protein) contributes to the symptomatology of the X linked lymphoproliferative disease. Cell Cycle 2009; 8:3086-90; PMID:19738428; http://dx.doi.org/10.4161/cc.8.19.9636.
23. van Leeuwen IM, Higgins M, Campbell J, Brown CJ, McCarthy AR, Pirrie L, et al. Mechanism-specific signatures for small-molecule p53 activators. Cell Cycle 2011; 10:1590-8; PMID:21490429; http://dx.doi.org/10.4161/cc.10.10.15519.
24. Okamoto S, Ji H, Howie D, Clarke K, Gullo C, Manning S, et al. Expression of the SH2D1A gene is regulated by a combination of transcriptional and post-transcriptional mechanisms. Eur J Immunol 2004; 34:3176-86; PMID:15459902; http://dx.doi.org/10.1002/eji.200324755.
25. Bhat NK, Thompson CB, Lindsten T, June CH, Fujiwara S, Koizumi S, et al. Reciprocal expression of human ETS1 and ETS2 genes during T-cell activation: regulatory role for the protooncogene ETS1. Proc Natl Acad Sci USA 1990; 87:3723-7; PMID:2187191; http://dx.doi.org/10.1073/pnas.87.10.3723.
26. Bulanova EG, Budagyan VM, Yarilin AA, Mazurenko NN. Expression of protooncogenes during lymphocyte activation by growth factors. Biochemistry (Mosc) 1997; 62:1021-5; PMID:9457764.
27. Terada N, Lucas JJ, Gelfand EW. Differential regulation of the tumor suppressor molecules, retinoblastoma susceptibility gene product (Rb) and p53, during cell cycle progression of normal human T cells. J Immunol 1991; 147:698-704; PMID:1906503.
28. VanAman SE, Whisler RL. Differential expression of p53 tumor suppressor protein and IL-2 in activated T cells from elderly humans. J Interferon Cytokine Res 1998; 18:315-20; PMID:9620358; http://dx.doi.org/10.1089/jir.1998.18.315.
29. Dhein J, Walczak H, Bäumler C, Debatin KM, Krammer PH. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 1995; 373:438-41; PMID:7530335; http://dx.doi.org/10.1038/373438a0.
30. Luiten RM, Péne J, Yssel H, Spits H. Ectopic hTERT expression extends the life span of human CD4+ helper and regulatory T-cell clones and confers resistance to oxidative stress-induced apoptosis. Blood 2003; 101:4512-9; PMID:12586632; http://dx.doi.org/10.1182/blood-2002-07-2018.
31. Roth A, Yssel H, Pene J, Chavez EA, Schertzer M, Lansdorp PM, et al. Telomerase levels control the lifespan of human T lymphocytes. Blood 2003; 102:849-57; PMID:12689947; http://dx.doi.org/10.1182/blood-2002-07-2015.
32. Kanaya T, Kyo S, Hamada K, Takakura M, Kitagawa Y, Harada H, et al. Adenoviral expression of p53 represses telomerase activity through down-regulation of human telomerase reverse transcriptase transcription. Clin Cancer Res 2000; 6:1239-47; PMID:10778946.
33. Xu D, Wang Q, Gruber A, Björkholm M, Chen Z, Zaid A, et al. Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells. Oncogene 2000; 19:5123-33; PMID:11064449; http://dx.doi.org/10.1038/sj.onc.1203890.
34. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr., Butel JS, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356:215-21; PMID:1552940; http://dx.doi.org/ 10.1038/356215a0.
35. Donehower LA, Harvey M, Vogel H, McArthur MJ, Montgomery CA Jr., Park SH, et al. Effects of genetic background on tumorigenesis in p53-deficient mice. Mol Carcinog 1995; 14:16-22; PMID:7546219; http://dx.doi.org/10.1002/mc. 2940140105.
36. Zhou X, Wong S, Walter J, Jacks T, Eisen HN. Increased generation of CD8+ T cell clones in p53 mutant mice. J Immunol 1999; 162:3957-60; PMID:10201915.
37. Gimeno R, Weijer K, Voordouw A, Uittenbogaart CH, Legrand N, Alves NL, et al. Monitoring the effect of gene silencing by RNA interference in human CD34+ cells injected into newborn RAG2-/- gammac-/- mice: functional inactivation of p53 in developing T cells. Blood 2004; 104:3886-93; PMID:15319293; http://dx.doi.org/10.1182/blood-2004-02-0656.
38. Fredersdorf S, Milne AW, Hall PA, Lu X. Characterization of a panel of novel anti-p21Waf1/Cip1 monoclonal antibodies and immunochemical analysis of p21Waf1/Cip1 expression in normal human tissues. Am J Pathol 1996; 148:825-35; PMID:8774137.